STAT

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

In TV drug ads, the numbers that will soon flash across screens are likely to be confusing and, in many cases, irrelevant.

In a fit of hubris, President Trump believes he is making drug makers “come clean” by forcing them to mention list prices in their TV ads.

If only it were that simple.

The reality is that last week’s mandate may, indeed, prod recalcitrant drug makers to pay more attention to pricing and, in some cases, cast this or that company in a greedy light. But for the most part, the numbers that will soon flash across screens are likely to be confusing and, in many cases, irrelevant.

Why do I say that?

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks